Informationstyper: PRM

Stayble Therapeutics announced today that recruiting patients for the company’s ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to the covid-19 pandemic and the strict pandemic rules with several lock-downs in all study countries. Under current conditions, the company is expected to be able to report study results during the second half of 2022, which is later than previously communicated.

Stayble Therapeutics today announced that the company’s scientific advisory board gains new expertise through the appointment of Professor Hans Jörg Meisel, Berlin, Germany. Prof. Meisel adds further expertise in medical innovation and clinical trials in degenerative spinal diseases and a European perspective to the company’s scientific advisory board.

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8 March 2021 and stop day will be on 10 March 2021.

The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a total of approximately 268 percent by existing shareholders and the public. Guarantee commitments made in connection with the rights issue will therefore not be utilized. Stayble will thus receive approximately SEK 41.5 million before transaction related costs. The capital that Stayble is now provided is intended to finance the Company’s operations until completion and processing of the results from the Company’s ongoing clinical Phase 2b trial and to give Stayble the opportunity to initiate discussions with potential partners to drive the project further through clinical Phase 3 studies until market approval. Settlement notes are expected to be sent out today, 22 February 2021.

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share (“BTA”), in connection with the Company’s ongoing rights issue, has been rescheduled for tomorrow, Thursday, 4 February 2021 due to an administrative and technical delay. The first day of trading in subscription rights and BTA was previously planned for today, 3 February 2021.

Today is the first day of the subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new issue of shares with preferential rights for existing shareholders (the “Rights Issue”). The general public is also given the opportunity to subscribe for shares in the Rights Issue. The subscription period lasts until 17 February 2021 and a fully subscribed Rights Issue will provide the Company with approximately SEK 41.5 million before issue costs. Stayble has received subscription commitments and guarantee (top-down) commitments in advance, corresponding to a total of approximately 84 per cent of the Rights Issue. The prospectus, teaser and subscription forms are available on the websites of the Company (www.staybletherapeutics.se), Sedermera Fondkommission (www.sedermera.se) and Nordic Issuing (www.nordic-issuing.se). It is also possible to subscribe for shares by using BankID through Sedermera Fondkommission’s or Nordic Issuing’s respective websites.

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday, 3 February 2021. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and will be available on their website (www.fi.se). The prospectus is also available on the websites of the Company (www.staybletherapeutics.se), Sedermera Fondkommission (www.sedermera.se) and Nordic Issuing (www.nordic-issuing.se). Teaser and subscription forms will be published on the above-mentioned websites in connection with the start of the subscription period.  

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday, 3 February 2021. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and will be available on their website (www.fi.se). The prospectus is also available on the websites of the Company (www.staybletherapeutics.se), Sedermera Fondkommission (www.sedermera.se) and Nordic Issuing (www.nordic-issuing.se). Teaser and subscription forms will be published on the above-mentioned websites in connection with the start of the subscription period.  

Stayble Therapeutics today announced that the company’s continue to strengthen its scientific advisory board with two new members – Dr. Aaron Calodney and Dr. Douglas Beall. Their respective expertise and experience within spine-related issues and pain management adds important insights as well as US perspectives.

Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Board of Directors, with support of the authorization from the Annual General Meeting in 2019, has resolved on a new issue of shares in which the public is also given the opportunity to participate . The rights issue can provide the Company with a maximum of approximately SEK 41.5 million before issue costs. Prior to the rights issue, existing shareholders and external investors have entered subscription commitments totalling approximately SEK 19.8 million (corresponding to approximately 48 percent of the rights issue). In addition, Stayble has procured guarantee (so-called top-down or top guarantee) of a total of approximately SEK 15 million (corresponding to approximately 36 percent of the rights issue). In total, the Company has thus received subscription and guarantee commitments corresponding to approximately 84 percent of the rights issue. Due to the rights issue, it is also announced that the time for publication of the Company’s year-end report for 2020 will be postponed to the 31[st] of March 2021.

In total, 7,122 warrants were exercised, corresponding to approximately 0.3 percent of the outstanding warrants, for subscription of 7 122 shares at a subscription price of SEK 12.30 per share. Through the exercise of these warrant, Stayble will receive approximately SEK 88 thousand before issuing costs.

Today is the first day of exercise TO1 for subsription to company shares that extend to December 1, 2020. Every one warrent gives the right to subscribe one new share in the Company to an exercise price of SEK 12,30 per share.

Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of units where one unit consisted of one newly issued share and one warrant free of charge. Each warrant gives the right to subscribe one new share in the Company. The subscribtion price has been set to SEK 12,30 which is in the range of the terms and condition in the prospectus that was published in conection with the issue of units.

Stayble Therapeutics today announced that Professor Anders Lehmann, VP Development, will give a talk entitled ”Sclerosation of the intervertebral disc using lactic acid in patients with discogenic chronic low back pain: results from a phase 1b trial” at the EuroSpine Annual Meeting. The conference will be held virtually on October 6-9, 2020.

Stayble Therapeutics today announced that the Company has initiated the first clinic in Spain for its clinical phase 2b study with the drug candidate STA363. Patient recruitment will commence immediately. The Company has now initiated clinics in all the three countries where it plans to conduct the study: the Netherlands, Russia and Spain. STA363 is intended for patients suffering from chronic disc-related low back pain.

A scientific article based on pre-clinical studies and the clinical phase 1b study with STA363 has been published in the highly prestigious scientific journal Spine.

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously initiated clinics in Russia. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously initiated clinics in Russia. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated and now recruiting patients. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.